JP2016505612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505612A5 JP2016505612A5 JP2015551182A JP2015551182A JP2016505612A5 JP 2016505612 A5 JP2016505612 A5 JP 2016505612A5 JP 2015551182 A JP2015551182 A JP 2015551182A JP 2015551182 A JP2015551182 A JP 2015551182A JP 2016505612 A5 JP2016505612 A5 JP 2016505612A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- skin
- seq
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 13
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 9
- 101150036847 NOX1 gene Proteins 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000005855 radiation Effects 0.000 claims 5
- 102000004019 NADPH Oxidase 1 Human genes 0.000 claims 4
- 108090000424 NADPH Oxidase 1 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003711 photoprotective effect Effects 0.000 claims 3
- 210000004761 scalp Anatomy 0.000 claims 3
- 230000037380 skin damage Effects 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims 1
- UAXAYRSMIDOXCU-BJDJZHNGSA-N 2-[[(2r)-2-[[(2s)-2-[[2-[[(2s)-4-amino-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]acetic acid Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O UAXAYRSMIDOXCU-BJDJZHNGSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 102000004400 Aminopeptidases Human genes 0.000 claims 1
- 108090000915 Aminopeptidases Proteins 0.000 claims 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 108010047562 NGR peptide Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 206010049422 Precancerous skin lesion Diseases 0.000 claims 1
- 206010063493 Premature ageing Diseases 0.000 claims 1
- 208000032038 Premature aging Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 claims 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 108010043655 penetratin Proteins 0.000 claims 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000004224 protection Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13150187.6A EP2752196A1 (en) | 2013-01-03 | 2013-01-03 | Selective nox-1 inhibitor peptides and uses thereof |
| EP13150187.6 | 2013-01-03 | ||
| PCT/EP2014/050063 WO2014106649A1 (en) | 2013-01-03 | 2014-01-03 | Selective nox-1 inhibitor peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505612A JP2016505612A (ja) | 2016-02-25 |
| JP2016505612A5 true JP2016505612A5 (enExample) | 2017-02-09 |
| JP6488237B2 JP6488237B2 (ja) | 2019-03-20 |
Family
ID=47458818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551182A Active JP6488237B2 (ja) | 2013-01-03 | 2014-01-03 | 選択的ｎｏｘ−１インヒビターペプチドおよびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170000842A9 (enExample) |
| EP (2) | EP2752196A1 (enExample) |
| JP (1) | JP6488237B2 (enExample) |
| CN (1) | CN105007933A (enExample) |
| AU (1) | AU2014204309B2 (enExample) |
| BR (1) | BR112015015242B1 (enExample) |
| CA (1) | CA2894576A1 (enExample) |
| DK (1) | DK2941268T3 (enExample) |
| HU (1) | HUE050715T2 (enExample) |
| IL (1) | IL239762B (enExample) |
| MA (1) | MA38296B2 (enExample) |
| RU (1) | RU2699726C2 (enExample) |
| TN (1) | TN2015000295A1 (enExample) |
| WO (1) | WO2014106649A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3034500A1 (en) | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| JP6472693B2 (ja) * | 2015-03-24 | 2019-02-20 | 株式会社荏原製作所 | 基板処理装置 |
| US20170110622A1 (en) * | 2015-10-14 | 2017-04-20 | Solarcity Corporation | Apparatus for electroplating of electrodes on photovoltaic structures |
| WO2019023263A1 (en) * | 2017-07-25 | 2019-01-31 | Immune Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR TREATING TUMORS COMPRISING A BCR-ABL1 FUSION GENE |
| EP3628669A1 (en) | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| SG11202102674RA (en) * | 2018-10-05 | 2021-04-29 | Pfizer | Boron containing pde4 inhibitors |
| AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| KR20210129517A (ko) * | 2020-04-20 | 2021-10-28 | 경북대학교병원 | Nadph 산화효소 1 저해제를 유효성분으로 포함하는 허혈-재관류 손상 예방 또는 치료용 조성물 |
| CN113773394B (zh) * | 2020-06-10 | 2023-10-27 | 山东大学 | 一种融合肽及在制备抗肿瘤制剂中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593966A (en) * | 1989-03-31 | 1997-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide derivatives of cytochrome b558 and their use as medicaments |
| US5726155A (en) * | 1993-08-02 | 1998-03-10 | The Scripps Research Institute | Regulation of oxidative burst using LMWG-derived peptides and analogs |
| GB2285047B (en) * | 1993-12-21 | 1998-04-15 | Yamanouchi U K Ltd | Polypeptides which inhibit the NADPH oxidase complex |
| AU2159895A (en) * | 1994-03-11 | 1995-09-25 | Ariad Pharmaceuticals, Inc. | Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains |
| US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| JP4215274B2 (ja) * | 1994-07-22 | 2009-01-28 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | Ｓｒｃ ＳＨ３結合性ペプチドとその分離法と利用法 |
| US6713605B1 (en) * | 1996-04-10 | 2004-03-30 | Kansas State University Research Foundation | Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| JP2005168329A (ja) * | 2003-12-08 | 2005-06-30 | Hokkaido Univ | Ｎａｄｐｈオキシダーゼ活性を阻害するポリペプチド |
| US7582606B2 (en) * | 2005-11-03 | 2009-09-01 | The Board Of Regents Of The University Of Texas System | Nadph oxidase cytosolic cofactor mutant |
| US20100119533A1 (en) * | 2007-03-07 | 2010-05-13 | Cornelius Joseph Clancy | Polynucleotides and Polypeptides Identified by IVIAT Screening and Methods of Use |
| JP2011515466A (ja) * | 2008-03-28 | 2011-05-19 | ニュースキン インターナショナル インコーポレイテッド | 反応性酸素種の阻害のためのａｒｎｏｘ阻害物質を含む組成物 |
| WO2013074816A2 (en) | 2011-11-15 | 2013-05-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel inhibitors of nox1 |
-
2013
- 2013-01-03 EP EP13150187.6A patent/EP2752196A1/en not_active Withdrawn
-
2014
- 2014-01-03 CN CN201480003978.1A patent/CN105007933A/zh active Pending
- 2014-01-03 DK DK14700063.2T patent/DK2941268T3/da active
- 2014-01-03 WO PCT/EP2014/050063 patent/WO2014106649A1/en not_active Ceased
- 2014-01-03 EP EP14700063.2A patent/EP2941268B1/en active Active
- 2014-01-03 RU RU2015132087A patent/RU2699726C2/ru not_active IP Right Cessation
- 2014-01-03 US US14/758,991 patent/US20170000842A9/en not_active Abandoned
- 2014-01-03 HU HUE14700063A patent/HUE050715T2/hu unknown
- 2014-01-03 BR BR112015015242-2A patent/BR112015015242B1/pt not_active IP Right Cessation
- 2014-01-03 JP JP2015551182A patent/JP6488237B2/ja active Active
- 2014-01-03 MA MA38296A patent/MA38296B2/fr unknown
- 2014-01-03 AU AU2014204309A patent/AU2014204309B2/en active Active
- 2014-01-03 CA CA2894576A patent/CA2894576A1/en not_active Abandoned
-
2015
- 2015-06-29 TN TNP2015000295A patent/TN2015000295A1/fr unknown
- 2015-07-02 IL IL239762A patent/IL239762B/en not_active IP Right Cessation
-
2017
- 2017-08-03 US US15/667,737 patent/US10517919B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505612A5 (enExample) | ||
| Sachdeva et al. | Nrf2 signaling is impaired in the aging RPE given an oxidative insult | |
| Guo et al. | Repetitive transcranial magnetic stimulation promotes neural stem cell proliferation via the regulation of MiR-25 in a rat model of focal cerebral ischemia | |
| RU2015132087A (ru) | Селективные ингибиторные пептиды nox-1 и их применение | |
| MY200087A (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| JP2018536689A5 (enExample) | ||
| JP2018513104A5 (enExample) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| JP2014050390A5 (enExample) | ||
| NZ606480A (en) | Albumin binding peptide-mediated disease targeting | |
| JP2015516496A5 (enExample) | ||
| WO2008097927A3 (en) | Treatment and prevention of neurodegenerative diseases using gene therapy | |
| JP2012516879A5 (enExample) | ||
| WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
| WO2023006999A3 (en) | Mrnas for treatment or prophylaxis of liver diseases | |
| WO2009067520A3 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| Chen et al. | TIGAR suppresses seizures induced by kainic acid through inhibiting oxidative stress and neuronal apoptosis | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| WO2010023195A3 (en) | Compositions and methods for treating cancer | |
| JP2018517767A5 (enExample) | ||
| Fuereder et al. | Metal drugs become targeted | |
| Kim et al. | Curcuma xanthorrhiza extract and xanthorrhizol ameliorate cancer-induced adipose wasting in CT26-bearing mice by regulating lipid metabolism and adipose tissue browning | |
| Ming et al. | Therapeutic effect of oridonin on mice with prostate cancer | |
| JP2014523437A (ja) | 癌の予防および治療における効力のある薬剤としての新規亜鉛フィンガー様ペプチド組成物 | |
| Karen et al. | Pachyonychia congenita associated with median rhomboid glossitis |